Anne Li April 9th, 2017
Last week, the UK Government triggered Article 50, the official commitment to the UK leaving the European Union (EU) following the referendum. This marks the start of the negotiation process between the UK and EU on the terms of withdrawal. Since the UK public’s vote in favour of leaving the EU in June last year, we’ve been identifying the possible implications and opportunities that a new relationship with the EU could present for medical research and cancer patients. Below, our chief clinician, Professor Peter Johnson, shares some of the key areas we’ve been highlighting in our meetings with representatives in Westminster and Brussels and in our responses to parliamentary committee inquiries that have opened in recent months. And we’ll continue to focus on these issues now that the formal process to leave the EU has begun.
See original article at: http://www.cancerresearchuk.org/about-us/cancer-news/news-report/2017-04-03-nhs-cancer-waiting-time-targets-missed-in-northern-ireland